Use of antiptatelet therapy in a diabetic outpatient service of a large urban public hospital

Nutrition, Metabolism and Cardiovascular Diseases

Volumn 15, Issue 1, 2005, Pages 42-46

  Bruno, Alberto ^a   Grassi, Giorgio ^a   Dani, Franco ^a   Degiovanni, Mariella ^a   Maghenzani, Giorgio ^a   Pagano, Gianfranco ^b  

^a MOLINETTE HOSPITAL   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

Author keywords

Antiplatelet therapy; Outpatient service; Type 2 diabetes

Indexed keywords

ANTITHROMBOCYTIC AGENT; ACETYLSALICYLIC ACID;

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CONTROLLED STUDY; DATA BASE; FEMALE; HEALTH SERVICE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTPATIENT CARE; PATIENT SELECTION; PRESCRIPTION; PUBLIC HOSPITAL; RETROSPECTIVE STUDY; URBAN AREA; METHODOLOGY; MIDDLE AGED; PRIMARY PREVENTION; RISK FACTOR;

ADULT; AGED; AGED, 80 AND OVER; ASPIRIN; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; MALE; MIDDLE AGED; PLATELET AGGREGATION INHIBITORS; PRIMARY PREVENTION; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 17444417886     PISSN: 09394753     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.numecd.2004.04.001     Document Type: Article

References (31)

1. Colwell JA, Nesto RW. The platelet in diabetes focus on prevention of ischemic events. Diabetes Care 2003;26:2181-8.
2. Patrono C. Aspirin as an antiplatelet drug. N Engl J Med 1994;330:1287-94.
3. Mehta P. Aspirin in the prophylaxis of coronary artery disease. Curr Opin Cardiol 2002;17:552-8.
4. Hansson L, Zanchetti A, Carruthers SG, Dahlof B, Elmfeldt D, Julius S, et al. Effects of intensive blood-pressure lowering and low dose aspirin in patients with hypertension: principal results of the hypertension optimal treatment (HOT) randomized trial. Lancet 1998;351:1755-62.
5. Meigs JB, Stafford RS. Cardiovascular disease prevention practices by US physicians for patients with diabetes. J Gen Intern Med 2000;15:220-8.
6. ETDRS Investigators. Aspirin effects on mortality and morbidity in patients with diabetes mellitus. JAMA 1992;268:1292-300.
7. Steering Committee of the Physicians: Health study research group. Final report on the aspirin component of the ongoing physicians' health study. N Engl J Med 1989;321:129-35.
8. Collaborative Group of the Primary Prevention Project. Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomised trial in general practice. Lancet 2001;357:89-95.
9. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy. I. Prevention of death myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994;308:81-106.
10. Antithrombotic Trialists' Collaboration. Collaboration meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002;324:71-86.
11. Colwell JA. Aspirin therapy in diabetes (technical review). Diabetes Care 1997;20:1767-71.
12. American Diabetes Association. Aspirin therapy in diabetes (position statement). Diabetes Care 1997;20:1772-3.
13. American Diabetes Association. Aspirin therapy in diabetes (position statement). Diabetes Care 2003;26(Suppl. 1):S87-8.
14. American Diabetes Association. Standards of medical care for patients with diabetes mellitus (position statement). Diabetes Care 2003;26(Suppl. 1):S33-50.
15. WHO collaborative centre for drug statistic methodology, Guidelines for ATC classification and DDD assignment. Oslo: WHO; 1993.
16. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998;339:229-34.
17. Rolka DB, Fagot-Campagna AF, Venkat Narayan KM. Aspirin use among adults with diabetes estimated from the Third National Health and Nutrition Examination Survey. Diabetes Care 2001;24:197-201.
18. Wood DM, Plewe WE, Colman PG. Aspirin usage in a large teaching hospital diabetes clinic setting. Diabet Med 1999;16:605-8.
19. Connor PJ, Pronk NP, Tan AW, Rush WA, Gray RJ. Does professional advice influence aspirin use to prevent heart disease in an HMC population? Eff Clin Pract 1998;1:26-32.
20. Krumholz HM, Chen YT, Wang Y, Radford MJ. Aspirin and angiotensin-converting enzyme inhibitors among elderly survivors of hospitalisation for an acute myocardial infarction. Arch Intern Med 2001;161:538-44.
21. Giorda C. Ipertesione, dislipidemie, aggregazione piastrinica e coagulazione: I trattamenti. In: Giorda C, Nucolucci A, editors. Diabete Mellito di tipo 2 Complicanze e rischio cardiovascolare in ltalia. La valutazione della realta ̀ assistenziale (osservazioni di outcome research). Turin: Centra Scientifico Editore; 2003. p. 115-23.
22. Shahar E, Folsom AR, Romm FJ, Bisgard KM, Metcalf PA, Crum L, et al. Patterns of aspirin use in middle aged adults: the Atherosclerosis Risk in Communities (ARIC) Study. Am Heart J 1996;131:915-22.
23. Stafford RS. Aspirin use is low among United States outpatients with coronary artery disease. Circulation 2000;101:1097-101.
24. Montori VM, Bryant SC, O'Connor AM, Jorgensen NW, Walsh EE, Smith SA. Decisional attributes of patients with diabetes: the aspirin choice. Diabetes Care 2003;26:2804-9.
25. Filippi A, Sabatini A, Badioli L, Samani F, Mazzaglia G, Catapano A, et al. Effects of an automated electronic reminder in changing the antiplatelet drug - prescribing behavior among Italian general practitioners in diabetic patients: an intervention trial. Diabetes Care 2003;26:1497-500.
26. Meune C, Mahe I, Mourad JJ, Simoneau G, Knellwolf AL, Bergmann JF, et al. Interaction between angiotensin-converting enzyme inhibitors and aspirin: a review. Eur J Clin Pharmacol 2000;56:609-20.
27. Pitt B, Yusuf S, for the SOLVD Investigators. Studies of left ventricular dysfunction (SOLVD): subgroup results. J Am Coll Cardiol 1992;19:215A.
28. Teo KK, Yusuf S, Pfeffer M, Kober L, Hall A, Pogue J, et al. Effects of long-term treatment with angiotensin-converting enzyme inhibitors in the presence or absence of aspirin: a systematic review. Lancet 2002;360:1037-43.
29. Guazzi M, Brambilla R, Reina G, Tumminello G, Guazzi MD. Aspirin-angiotensin-converting enzyme inhibitor coadministration and mortality in patients with heart failure. Arch Intern Med 2003;163:1574-9.
30. Wei J, Langnam MJS, Wainwright P. Peptic ulcer bleeding: accessory risk factors and interactions with non-steroidal anti-inflammatory drugs. Gut 2000;46(1):27-31.
31. Krein SL, Hogan MM, Vijan S, Kerr EA, Poigach LM. Aspirin use and counselling about aspirin among patients with diabetes. Diabetes Care 2002;25:965-70.